Navigation Links
Interleukin Genetics to Present at the 13th International Conference on Periodontal Research

Dr. Kenneth Kornman to Discuss Periodontal Inflammation and

Gene-Environment Interactions

WALTHAM, Mass., June 3 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (Amex: ILI), announced today that Dr. Kenneth Kornman, Chief Scientific Officer, will present at the 13th International Conference on Periodontal Research (ICPR) on June 6, 2008 in Ljubljana, Slovenia on the genetic and environmental factors that control inflammation differences among individuals. The ICPR meeting has been held approximately every three years since 1969 to bring together the world's leaders in periodontal research to reassess the current knowledge in the field and to identify new research direction, to improve the diagnosis, prevention, and treatment of periodontal diseases.

Periodontitis is a bacterially-induced chronic inflammatory disease that causes destruction of bone and other tissues that support the teeth. Severe periodontitis, that usually leads to loss of multiple teeth, is found in approximately 8-13 percent of the adult population. The presence and severity of periodontitis have been associated with an increased risk for other important inflammatory conditions, including pre-term births, cardiovascular disease, rheumatoid arthritis, and certain cancers.

WHO: Dr. Kenneth Kornman, Chief Scientific Officer of Interleukin


WHERE: 13th International Conference on Periodontal Research (ICPR) in

Ljubljana, Slovenia

WHEN: Friday, June 6, 2008 at 9:45-10:30 GMT

WHAT: Approximately 30-60 percent of the severity of periodontal disease

is determined by genetics. Interleukin Genetics developed and

markets the PST(R) genetic test to help identify individuals at

increased risk for severe periodontal disease and complications

from dental implants. This test helps dentists guide the

management of their patients' periodontal disease to avoid

complications of severe periodontitis.

About Interleukin Genetics

Interleukin Genetics, Inc. (Amex: ILI) is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin is headquartered in Waltham, MA. For more information about Interleukin, its products and ongoing programs, please visit

Certain statements contained herein are "forward-looking" statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns and our ability to make progress in advancing our core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the risk of market acceptance of our products, the risk of technology and product obsolescence, delays in product development, the performance of our commercial partners, the availability of adequate capital, the actions of our competitors and other competitive risks, and those risks and uncertainties described in our annual reports on Form 10-K, our quarterly reports on Form 10-Q and other documents we file with, or furnish to, the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.

SOURCE Interleukin Genetics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Interleukin Genetics Welcomes the Signing of the Genetic Information Nondiscrimination Act (GINA)
2. Interleukin Genetics to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
3. Interleukin Genetics Announces Conference Call and Webcast to Discuss First Quarter 2008 Business Results
4. Interleukin Genetics Appoints Eliot M. Lurier Chief Financial Officer
5. Interleukin Genetics Announces Conference Call and Webcast to Discuss Fourth Quarter and Year End 2007 Business Results
6. Interleukin Genetics Retains Top Life Science Communications Firms
7. Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor
8. Interleukin Genetics Announces Conversion of $2.04 Million of Debt Into Common Stock
9. Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results
10. Interleukin Genetics President and Chief Scientific Officer to Present at Immunotoxicology V Conference
11. Interleukin Genetics Announces Management and Board Appointments
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015  AbbVie, is introducing ... that focuses on a daily routine for managing the ... their medication can affect the way the body absorbs ... to their a daily routine are important. The goal ... help patients better manage their hypothyroidism by establishing a ...
(Date:11/30/2015)... 2015  Northwest Biotherapeutics (NASDAQ: NWBO ) ("NW ... therapies for solid tumor cancers, announced today that the ... and the Company welcomes Neil Woodford,s call ... anonymous internet report on NW Bio.  The Company,s Board ... Powers stated, "We agree with Mr. Woodford that, ...
(Date:11/30/2015)... and PETACH TIKVAH, Israel , Nov. ... BCLI ), a leading developer of adult stem cell ... Brainstorm Cell Therapeutics Ltd., has been awarded an additional grant ... of the Chief Scientist (OCS). This grant, the second this ... 2015 activities to approximately $1.8 million (approximately NIS7 million).  ...
(Date:11/27/2015)... CHESTERFIELD, United Kingdom , Nov. 27, 2015 /PRNewswire/--  ... specialty biopharmaceutical company, announced today that it has closed ... systems (CMDS) business to Guerbet (GBT- NYSE Euronext) in ... CMDS operations encompassed four manufacturing facilities and a total ... nearly 75 in the St. Louis ...
Breaking Biology Technology:
(Date:11/17/2015)... Mass. , Nov. 17, 2015 Pressure ... leader in the development and sale of broadly enabling, ... worldwide life sciences industry, today announced it has received ... its $5 million Private Placement (the "Offering"), increasing the ... $4,025,000.  One or more additional closings are expected in ...
(Date:11/12/2015)... , Nov. 12, 2015  Arxspan has entered ... MIT and Harvard for use of its ArxLab ... management tools. The partnership will support the institute,s ... and chemical research information internally and with external ... used for managing the Institute,s electronic laboratory notebook, ...
(Date:11/10/2015)... , Nov. 10, 2015  In ... on the basis of product, type, application, ... included in this report are consumables, services, ... report are safety biomarkers, efficacy biomarkers, and ... this report are diagnostics development, drug discovery ...
Breaking Biology News(10 mins):